Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 years or older
- People who have been diagnosed with endometrial cancer confirmed by a tissue sample (biopsy or similar test)
- People who are being considered for surgery as the main treatment, or who have recently had that surgery
- People who are willing and able to give their formal agreement to take part in the study
Who may not be able to join:
- People who have already received chemotherapy or radiation therapy for endometrial cancer (prior hormonal therapy for endometrial cancer is still allowed)
- People who had prior surgery for endometrial cancer and have since received chemotherapy or radiation therapy before enrolling
- People with a history of other cancers may need additional review — the trial doctor (Principal Investigator) would need to assess whether the risk of that cancer returning or spreading is considered low enough to allow participation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pamela T Soliman, M.D. Anderson Cancer Center
Phone: 713-745-2352
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of circulating cell free deoxyribonucleic acid (ccfDNA) mutations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.